STOCK TITAN

TerrAscend Reports Second Quarter 2024 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags

TerrAscend Corp. (TSX: TSND, OTCQX: TSNDF) reported its Q2 2024 financial results, showing strong growth and improved profitability. Key highlights include:

- Net Revenue of $77.5 million, up 7.5% year-over-year
- Gross Profit Margin of 48.6%
- Adjusted EBITDA from continuing operations of $15.6 million, a 21.9% increase year-over-year
- Free Cash Flow of $11.7 million
- Maintained #1 market share position in New Jersey throughout H1 2024

The company achieved its 8th consecutive quarter of positive cash flow from continuing operations. TerrAscend also closed a $140 million senior secured term loan, providing financial flexibility for future growth and expansion strategies.

TerrAscend Corp. (TSX: TSND, OTCQX: TSNDF) ha riportato i risultati finanziari del secondo trimestre del 2024, evidenziando una forte crescita e un miglioramento della redditività. I punti salienti includono:

- Ricavi netti di $77,5 milioni, con un aumento del 7,5% rispetto all'anno precedente
- Margine di profitto lordo del 48,6%
- EBITDA rettificato dalle operazioni continuative di $15,6 milioni, con un incremento del 21,9% rispetto all'anno precedente
- Flusso di cassa libero di $11,7 milioni
- Mantenimento della posizione di #1 in termini di quota di mercato nel New Jersey nel primo semestre del 2024

L'azienda ha raggiunto il suo ottavo trimestre consecutivo di flusso di cassa positivo dalle operazioni continuative. TerrAscend ha anche concluso un prestito a termine senior garantito di $140 milioni, fornendo flessibilità finanziaria per strategie di crescita ed espansione future.

TerrAscend Corp. (TSX: TSND, OTCQX: TSNDF) reportó sus resultados financieros del segundo trimestre de 2024, mostrando un sólido crecimiento y una rentabilidad mejorada. Los puntos destacados incluyen:

- Ingresos netos de $77,5 millones, un aumento del 7,5% interanual
- Margen de ganancia bruta del 48,6%
- EBITDA ajustado de operaciones continuas de $15,6 millones, con un incremento del 21,9% interanual
- Flujo de caja libre de $11,7 millones
- Mantenimiento de la posición de #1 en participación de mercado en Nueva Jersey durante el primer semestre de 2024

La compañía logró su octavo trimestre consecutivo de flujo de caja positivo de operaciones continuas. TerrAscend también cerró un préstamo a plazo senior asegurado de $140 millones, proporcionando flexibilidad financiera para estrategias de crecimiento y expansión futuras.

TerrAscend Corp. (TSX: TSND, OTCQX: TSNDF)는 2024년 2분기 재무 실적을 보고하며 강력한 성장과 개선된 수익성을 보여주었습니다. 주요 사항은 다음과 같습니다:

- 순수익 7천750만 달러, 전년 대비 7.5% 증가
- 총 이익률 48.6%
- 계속 운영에서 조정된 EBITDA 1천560만 달러, 전년 대비 21.9% 증가
- 자유 현금 흐름 1천170만 달러
- 2024년 상반기 동안 뉴저지에서 #1 시장 점유율 유지

회사는 계속 운영에서 긍정적인 현금 흐름을 8분기 연속으로 달성했습니다. TerrAscend는 또한 1억4천만 달러의 고급 담보 이자 비용 대출 계약을 체결하여 향후 성장 및 확장 전략에 대한 재정적 유연성을 제공합니다.

TerrAscend Corp. (TSX: TSND, OTCQX: TSNDF) a annoncé ses résultats financiers du deuxième trimestre 2024, montrant une forte croissance et une rentabilité améliorée. Les points forts comprennent :

- Revenus nets de 77,5 millions de dollars, soit une augmentation de 7,5 % par rapport à l'année précédente
- Marge bénéficiaire brute de 48,6%
- EBITDA ajusté des opérations continues de 15,6 millions de dollars, ce qui représente une augmentation de 21,9 % par rapport à l'année précédente
- Flux de trésorerie libre de 11,7 millions de dollars
- Maintien de la position de #1 en part de marché dans le New Jersey au cours du premier semestre 2024

L'entreprise a atteint son huitième trimestre consécutif de flux de trésorerie positif des opérations continues. TerrAscend a également finalisé un prêt à terme senior garanti de 140 millions de dollars, offrant une flexibilité financière pour les stratégies de croissance et d'expansion futures.

TerrAscend Corp. (TSX: TSND, OTCQX: TSNDF) hat seine finanziellen Ergebnisse für das zweite Quartal 2024 veröffentlicht und zeigt ein starkes Wachstum sowie eine verbesserte Rentabilität. Die wichtigsten Punkte umfassen:

- Nettoumsatz von 77,5 Millionen Dollar, ein Anstieg von 7,5% im Vergleich zum Vorjahr
- Bruttogewinnmarge von 48,6%
- Bereinigtes EBITDA aus fortgeführten Aktivitäten von 15,6 Millionen Dollar, was einen Anstieg von 21,9% im Vergleich zum Vorjahr bedeutet
- Freier Cashflow von 11,7 Millionen Dollar
- Beibehaltung der #1-Marktananteilsposition in New Jersey im ersten Halbjahr 2024

Das Unternehmen erzielte im achten aufeinanderfolgenden Quartal einen positiven Cashflow aus fortgeführten Aktivitäten. TerrAscend schloss zudem ein gesichertes Senior-Darlehen in Höhe von 140 Millionen Dollar ab, was finanzielle Flexibilität für zukünftige Wachstums- und Expansionsstrategien bietet.

Positive
  • Net Revenue increased by 7.5% year-over-year to $77.5 million
  • Adjusted EBITDA from continuing operations grew 21.9% year-over-year to $15.6 million
  • Free Cash Flow improved to $11.7 million from negative $0.2 million in Q2 2023
  • Maintained #1 market share position in New Jersey throughout H1 2024
  • Wholesale revenue increased by 75%, led by New Jersey, Pennsylvania, and Maryland
  • Closed a $140 million senior secured term loan for potential M&A and expansion
Negative
  • GAAP Net loss from continuing operations of $6.2 million
  • Gross Profit Margin decreased to 48.6% from 50.2% in Q2 2023
  • Retail revenue declined by 8.7% year-over-year, mainly in New Jersey and Michigan

Net Revenue of $77.5 million, an increase of 7.5% year-over-year

Cash Flow from continuing operations of $13.1 million and Free Cash Flow1 of $11.7 million

#1 market share position in New Jersey throughout first half of 2024

TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND, OTCQX: TSNDF), a leading North American cannabis company, today reported its financial results for the second quarter ended June 30, 2024. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles (“GAAP”), unless indicated otherwise. The financial results of the Company include all entities that are consolidated in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 (the “Consolidated Entities”). Any references in this press release to TerrAscend or the Company include references to the Company and the Consolidated Entities.

The following financial measures are reported as results from continuing operations due to the shutdown of the Company’s licensed producer business in Canada, which is reported as discontinued operations through September 30, 2023. All historical periods have been restated accordingly.

Second Quarter 2024 Financial Highlights

  • Net Revenue was $77.5 million, compared to $72.1 million, an increase of 7.5% year-over-year.
  • Gross Profit Margin was 48.6%, compared to 50.2% in Q2 2023.
  • GAAP Net loss from continuing operations was $6.2 million, compared to a net loss of $12.9 million in Q2 2023.
  • EBITDA from continuing operations1 was $18.6 million, compared to $6.5 million in Q2 2023, an increase of 186% year-over-year.
  • Adjusted EBITDA from continuing operations1 was $15.6 million, compared to $12.8 million in Q2 2023, an increase of 21.9% year-over-year.
  • Adjusted EBITDA Margin from continuing operations1 was 20.2%, compared to 17.8% in Q2 2023.
  • Net Cash provided by continuing operations was $13.1 million compared to $1.8 million in Q2 2023.
  • Free Cash Flow1 was $11.7 million compared to negative $0.2 million in Q2 2023.

“For the second quarter, revenue and EBITDA increased materially year-over-year and we delivered another quarter of positive free cash flow,” stated Jason Wild, Executive Chairman of TerrAscend. “We have the right team, high-performing assets, and a major differentiation in having a ‘wide open map’. This will enable us to strike accretive deals to enter attractive new states via best in breed operators. We are closing in on multiple transactions to expand our geographic footprint and the recent closing of our $140 million term loan provides financial flexibility and fuel to execute this growth strategy. We can’t wait to share more details, when appropriate.”

Financial Summary Q2 2024 and Comparative Periods
All figures are restated for the Canadian business recorded as discontinued operations through Q3 2023.

(in millions of U.S. Dollars) Q2 2024  Q2 2023 
Revenue, net  77.5   72.1 
Year-over-Year increase  7.5%  12.7%
       
Gross profit  37.7   36.2 
Gross profit margin  48.6%  50.2%
       
General & Administrative expenses  24.1   30.5 
Share-based compensation expense (included in G&A expenses above)  2.0   2.0 
G&A as a % of revenue, net  31.1%  42.3%
       
Net loss from continuing operations  (6.2)  (12.9)
       
EBITDA from continuing operations1  18.6   6.5 
       
Adjusted EBITDA from continuing operations1  15.6   12.8 
Adjusted EBITDA Margin from continuing operations1  20.2%  17.8%
       
Net cash provided by operations - continuing operations  13.1   1.8 
       
Free Cash Flow1  11.7   (0.2)

1. EBITDA from continuing operations, Adjusted EBITDA from continuing operations, Adjusted EBITDA Margin from continuing operations, and Free Cash Flow are non-GAAP measures defined in the section titled “Definition and Reconciliation of Non-GAAP Measures” below and reconciled to the most directly comparable GAAP measure, at the end of this release.

Second Quarter 2024 Business and Operational Highlights

  • Achieved 8th consecutive quarter of positive cash flow provided by continuing operations.
  • Achieved #1 market share position in New Jersey throughout the first half of 2024, according to BDSA.
  • Doubled Pennsylvania wholesale revenue year-over-year.
  • Doubled New Jersey wholesale revenue year-over-year.
  • Grew Maryland wholesale revenue by 117% year-over-year.
  • Delivered 40% gross margin in Michigan for the third consecutive quarter.
  • Celebrated the opening of new Detroit dispensary, GAGE 313.
  • Relocated and opened dispensary in Nottingham, Maryland.
  • Expanded cultivation capacity at Hagerstown, Maryland facility.

Subsequent Events

  • Closed on a senior secured term loan for gross proceeds of $140 million carrying an interest rate of 12.75%, maturing in August 2028, and containing no prepayment penalties or warrants.

Second Quarter 2024 Financial Results
Net revenue for the second quarter of 2024 was $77.5 million, an increase of 7.5% compared to $72.1 million for the second quarter of 2023. This growth was driven by a 75% increase in wholesale revenue led by New Jersey, Pennsylvania and Maryland, partially offset by an 8.7% decline year-over-year in retail revenue mainly driven by New Jersey and Michigan.

Gross profit margin for the second quarter of 2024 was 48.6% as compared to 50.2% in the second quarter of 2023. The year-over-year decrease of 160 basis points was driven by channel mix shift and retail price compression in New Jersey, partially offset by margin expansion in both Michigan and Maryland.

General & Administrative expenses (G&A) for the second quarter of 2024 were $24.1 million as compared to $30.5 million in the second quarter of 2023. G&A as a percent of revenue was 31.1% in the second quarter of 2024, compared to 42.3% in the second quarter of 2023. The reduction in G&A as a percent of revenue was driven by a $4.2 million reversal of a bad debt provision related to a legal settlement, combined with other underlying reductions across the business, while growing revenue by 7.5% year-over-year.

Net loss from continuing operations for the second quarter of 2024 was $6.2 million, compared to a net loss of $12.9 million in the second quarter of 2023. The improvement was driven by revenue growth while maintaining relatively stable gross profit margins and materially reducing G&A expenses.  

Adjusted EBITDA from continuing operations for the second quarter of 2024 grew 21.9% year-over-year to $15.6 million, representing a 20.2% Adjusted EBITDA margin, as compared to $12.8 million and 17.8% in the second quarter of 2023. The year-over-year improvement of 240 basis points was driven by G&A expense leverage, partially offset by the decline in gross margin.  

Balance Sheet and Cash Flow
Cash and cash equivalents, including restricted cash, were $30.5 million as of June 30, 2024, compared to $25.7 million as of March 31, 2024. Net cash provided by continuing operations was $13.1 million for the second quarter of 2024 compared to $1.8 million in the second quarter of 2023. This represented the Company’s eighth consecutive quarter of positive cash flow from continuing operations. The second quarter of 2024 included an $8.4 million federal tax refund related to certain amended tax returns for Consolidated Entities. Capex spending was $1.4 million in the second quarter of 2024 mainly related to the completion of the Company’s Hagerstown, Maryland expansion which doubled the output capacity at that site. Free cash flow was $11.7 million as compared to ($0.2) million in the second quarter of 2023. During the second quarter of 2024, payments were made related to $5.8 million of debt paydown and $1.2 million for distributions to the Company’s New Jersey minority partners.

Subsequent to the end of the quarter, the Company closed on a senior secured term loan (the “Loan”) for gross proceeds of $140 million from funds managed by FocusGrowth Asset Management, LP (“FocusGrowth”), a leading capital provider to the cannabis sector, along with other members of a loan syndicate. The Loan includes an initial draw of $114 million in gross proceeds by certain of the Consolidated Entities in Pennsylvania, Maryland and California, with a second draw of $26 million in gross proceeds expected in September 2024 by the Consolidated Entities in Michigan. The Loan carries an interest rate of 12.75%, matures in August 2028, contains no prepayment penalties, and is guaranteed by the Company and TerrAscend USA, Inc. No warrants were issued as part of the Loan. The proceeds from the initial draw were used to retire the Company’s existing indebtedness in Pennsylvania with the remainder available for potential M&A transactions focused on geographic expansion. The proceeds from the second draw will be used to retire the Company’s existing indebtedness in Michigan.

As of August 7, 2024, there were approximately 368 million basic shares of the Company issued and outstanding, including 291 million Company common shares, 13 million Company preferred shares, as converted, and 63 million Company exchangeable shares. Additionally, there are 44 million warrants and options outstanding at a weighted average price of $3.84.

Conference Call
TerrAscend will host a conference call today, August 8, 2024, to discuss these results. Jason Wild, Executive Chairman, Ziad Ghanem, President and Chief Executive Officer, and Keith Stauffer, Chief Financial Officer, will host the call starting at 5:00 p.m. Eastern time. A question-and-answer session will follow management's presentation.

Date:Thursday, August 8, 2024
Time:5:00 p.m. Eastern Time
Webcast:https://app.webinar.net/LVQnp1BkreY
Dial-in Number:1-888-664-6392
Replay:



416-764-8677 or 1-888-390-0541

Available until 12:00 midnight Eastern Time Thursday, August 22, 2024
Replay Entry Code: 532477#

Financial results and analyses are available on the Company’s website (www.terrascend.com), the SEC's Electronic Data Gathering and Analysis Retrieval System (EDGAR) (www.sec.gov), and SEDAR+ (www.sedarplus.ca).

The Toronto Stock Exchange (“TSX”) has neither approved nor disapproved the contents of this news release. Neither the TSX nor any securities regulator accepts responsibility for the adequacy or accuracy of this release.

About TerrAscend
TerrAscend is a leading TSX-listed cannabis company with interests across the North American cannabis sector, including vertically integrated operations in Pennsylvania, New Jersey, Maryland, Michigan and California through TerrAscend Growth Corp. and retail operations in Canada through TerrAscend Canada Inc.. TerrAscend operates The Apothecarium, Gage and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns or licenses several synergistic businesses and brands including Gage Cannabis, The Apothecarium, Cookies, Lemonnade, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana, and Valhalla Confections. For more information visit www.terrascend.com.

Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute, or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend's operations and financial performance.

Forward Looking Information
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and include statements with respect to the Company’s expectations regarding the financial and other benefits of the Loan to the Company’s operations and growth strategy; the Company’s expected use of proceeds from the Loan; the Company’s potential expansion into other markets and U.S federal regulatory reform. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; and the risk factors set out in the Company’s most recently filed MD&A, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and in the section titled “Risk Factors” in the Company’s Annual Report for the year ended December 31, 2023 filed with the Securities and Exchange Commission on March 14, 2024.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether, as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

Definition and Reconciliation of Non-GAAP Measures
In addition to reporting the financial results in accordance with GAAP, the Company reports certain financial results that differ from what is reported under GAAP. Non-GAAP measures used by management do not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company believes that certain investors and analysts use these measures to measure a company’s ability to meet other payment obligations or as a common measurement to value companies in the cannabis industry, and the Company calculates: (i) EBITDA from continuing operations and Adjusted EBITDA from continuing operations as net loss, adjusted to exclude provision for income taxes, finance expenses, depreciation and amortization, share-based compensation, loss from revaluation of contingent consideration, gain on fair value of derivative liabilities and purchase option derivative assets, gain on lease termination, and certain other items, which management believes is not reflective of the ongoing operations and performance, (ii) Adjusted EBITDA Margin from continuing operations as EBITDA from continuing operations adjusted for certain material non-cash items such as share-based compensation, loss from revaluation of contingent consideration, gain on fair value of derivative liabilities and purchase option derivative assets, gain on lease termination, certain other items, which management believes is not reflective of the ongoing operations and performance of the Company, (iii) Free Cash Flow as net cash provided by operating activities from continuing operations as presented in the Consolidated Statements of Cash Flows, less capital expenditures for property and equipment, and (iv) General & Administrative expenses excluding stock-based compensation as a percentage of Revenue, net. Such information is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. The Company believes this definition is a useful measure to assess the performance of the Company as it provides more meaningful operating results by excluding the effects of expenses that are not reflective of the Company’s underlying business performance and other one-time or non-recurring expenses.

For more information regarding TerrAscend: 
Keith Stauffer
Chief Financial Officer
ir@terrascend.com
855-837-7295

TerrAscend Corp.
Consolidated Balance Sheet
(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

  At
June 30, 2024
  At
December 31, 2023
 
Assets      
Current assets      
Cash and cash equivalents $27,378  $22,241 
Restricted cash  3,113   3,106 
Accounts receivable, net  16,799   19,048 
Investments  1,737   1,913 
Inventory  51,009   51,683 
Prepaid expenses and other current assets  4,771   4,898 
Total current assets  104,807   102,889 
Non-current assets      
Property and equipment, net  193,340   196,215 
Deposits  284   337 
Operating lease right of use assets  41,645   43,440 
Intangible assets, net  212,515   215,854 
Goodwill  106,929   106,929 
Other non-current assets  724   854 
Total non-current assets  555,437   563,629 
Total assets $660,244  $666,518 
       
Liabilities and shareholders' equity      
Current liabilities      
Accounts payable and accrued liabilities $46,918  $49,897 
Deferred revenue  4,699   4,154 
Loans payable, current  15,946   137,737 
Contingent consideration payable, current  2,632   6,446 
Operating lease liability, current  2,330   1,244 
Derivative liability, current  899    
Lease obligations under finance leases, current  93   2,030 
Corporate income tax payable  3,184   4,775 
Other current liabilities  756   717 
Total current liabilities  77,457   207,000 
Non-current liabilities      
Loans payable, non-current  171,926   61,633 
Operating lease liability, non-current  42,654   45,384 
Lease obligations under finance leases, non-current  2,140   407 
Derivative liability, non-current  2,253   5,162 
Convertible debt  8,126   7,266 
Deferred income tax liability  16,760   17,175 
Contingent consideration payable, non-current  2,109    
Liability on uncertain tax position and other long term liabilities  110,673   81,751 
Total non-current liabilities  356,641   218,778 
Total liabilities  434,098   425,778 
Commitments and contingencies      
Shareholders' equity      
Share capital      
Series A, convertible preferred stock, no par value, unlimited shares authorized; 12,350 and 12,350 shares outstanding as of June 30, 2024 and December 31, 2023, respectively      
Series B, convertible preferred stock, no par value, unlimited shares authorized; 600 and 600 shares outstanding as of June 30, 2024 and December 31, 2023, respectively      
Series C, convertible preferred stock, no par value, unlimited shares authorized; nil and nil shares outstanding as of June 30, 2024 and December 31, 2023, respectively      
Series D, convertible preferred stock, no par value, unlimited shares authorized; nil and nil shares outstanding as of June 30, 2024 and December 31, 2023, respectively      
Proportionate voting shares, no par value, unlimited shares authorized; nil and nil shares outstanding as of June 30, 2024 and December 31, 2023, respectively      
Exchangeable shares, no par value, unlimited shares authorized; 63,492,038 and 63,492,038 shares outstanding as of June 30, 2024 and December 31, 2023, respectively      
Common shares, no par value, unlimited shares authorized; 291,507,430 and 288,327,497 shares outstanding as of June 30, 2024 and December 31, 2023, respectively      
Additional paid in capital  945,797   944,859 
Accumulated other comprehensive income  2,457   1,799 
Accumulated deficit  (723,590)  (704,162)
Non-controlling interest  1,482   (1,756)
Total shareholders' equity  226,146   240,740 
Total liabilities and shareholders' equity $660,244  $666,518 


TerrAscend Corp.
Consolidated Statements of Operations and Comprehensive Loss
(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

   For the Three Months Ended  For the Six Months Ended 
   June 30, 2024  June 30, 2023   June 30, 2024  June 30, 2023 
Revenue, net  $77,523  $72,124   $158,156  $141,522 
               
Cost of sales   39,840   35,898    81,742   71,396 
               
Gross profit   37,683   36,226    76,414   70,126 
               
Operating expenses:              
General and administrative   24,060   30,476    52,068   58,206 
Amortization and depreciation   2,190   2,242    4,405   4,271 
Impairment of property and equipment and right of use assets          2,438   28 
Other operating (income) expense   (1,186)  10    (1,186)  317 
Total operating expenses   25,064   32,728    57,725   62,822 
               
Income from operations   12,619   3,498    18,689   7,304 
               
Other expense (income)              
Loss from revaluation of contingent consideration   1,827       3,220    
Gain on fair value of derivative liabilities and purchase option derivative assets   (2,922)  (215)   (1,939)  (653)
Finance and other expenses   8,891   8,171    17,480   18,258 
Transaction and restructuring costs      389       392 
Unrealized and realized foreign exchange loss (gain)   104   (101)   389   (132)
Unrealized and realized loss on investments   227   1,661    227   2,360 
Income (loss) from continuing operations before provision for income taxes   4,492   (6,407)   (688)  (12,921)
Provision for income taxes   10,729   6,448    20,400   19,112 
Net loss from continuing operations  $(6,237) $(12,855)  $(21,088) $(32,033)
               
Discontinued operations:              
Loss from discontinued operations, net of tax  $  $(621)  $  $(4,212)
Net loss  $(6,237) $(13,476)  $(21,088) $(36,245)
               
Foreign currency translation adjustment   (260)  408    (658)  755 
Comprehensive loss  $(5,977) $(13,884)  $(20,430) $(37,000)
               
Net loss from continuing operations attributable to:              
Common and proportionate Shareholders of the Company  $(8,180) $(14,998)  $(25,235) $(36,362)
Non-controlling interests  $1,943  $2,143   $4,147  $4,329 
               
Comprehensive loss attributable to:              
Common and proportionate Shareholders of the Company  $(7,920) $(16,027)  $(24,577) $(41,329)
Non-controlling interests  $1,943  $2,143   $4,147  $4,329 
               
Net loss per share - basic:              
Continuing operations  $(0.03) $(0.05)  $(0.09) $(0.13)
Discontinued operations             (0.02)
Net loss per share - basic  $(0.03) $(0.05)  $(0.09) $(0.15)
               
Weighted average number of outstanding common shares   291,488,661   275,186,279    291,053,614   271,223,233 
               
Net loss per share - diluted:              
Continuing operations  $(0.03) $(0.05)  $(0.09) $(0.13)
Discontinued operations            $(0.02)
Net loss per share - diluted  $(0.03) $(0.05)  $(0.09) $(0.15)
               
Weighted average number of outstanding common shares, assuming dilution   291,488,661   275,186,279    291,053,614   271,223,233 


TerrAscend Corp.
Consolidated Statements of Cash Flows
(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

 For the Six Months Ended 
 June 30, 2024  June 30, 2023 
Operating activities     
Net loss from continuing operations$(21,088) $(32,033)
Adjustments to reconcile net loss to net cash provided by operating activities     
Non-cash adjustments of inventory    1,081 
Accretion expense 8,375   5,673 
Depreciation of property and equipment and amortization of intangible assets 9,993   9,761 
Amortization of operating right-of-use assets 1,481   932 
Share-based compensation 3,446   3,694 
Deferred income tax (recovery) expense (415)  815 
Gain on fair value of derivative liabilities and purchase option derivative assets (1,939)  (653)
Gain on disposal of fixed assets (17)  345 
Unrealized and realized loss on investments 227   2,410 
Loss from revaluation of contingent consideration 3,220    
Impairment of property and equipment and right of use assets 2,438    
Gain on lease termination (1,169)   
Bad debt recovery (1,307)  (23)
Unrealized and realized foreign exchange loss (gain) 389   (132)
Changes in operating assets and liabilities     
Receivables 1,358   318 
Inventory 1,970   (7,851)
Prepaid expense and other current assets 119   (319)
Deposits 53   431 
Other assets 77   714 
Accounts payable and accrued liabilities and other payables (8,019)  4,089 
Operating lease liability (1,147)  (337)
Other liability (536)  (173)
Uncertain tax position liabilities 29,917   1,258 
Corporate income tax payable (1,591)  22,127 
Deferred revenue 545   157 
Net cash provided by operating activities- continuing operations 26,380   12,284 
Net cash used in operating activities - discontinued operations    (3,164)
Net cash provided by operating activities 26,380   9,120 
      
Investing activities     
Investment in property and equipment (4,272)  (4,504)
Investment in intangible assets (699)  (262)
Principal payments received on lease receivable    104 
Insurance recovery for property and equipment 871    
Receipt of convertible debenture payment    738 
Payment for land contracts (478)  (769)
Cash portion of consideration paid in acquisitions, net of cash of acquired (250)  (14,469)
Net cash used in investing activities - continuing operations (4,828)  (19,162)
Net cash provided investing activities - discontinued operations    14,285 
Net cash used in investing activities (4,828)  (4,877)
      
Financing activities     
Transfer of Employee Retention Credit    12,677 
Proceeds from loan payable, net of transaction costs 3,137   23,872 
Proceeds from options and warrants exercised    81 
Loan principal paid (18,048)  (40,359)
Loan amendment fee paid and prepayment premium paid    (1,178)
Capital distributions paid to non-controlling interests (1,564)  (3,415)
Proceeds from private placement, net of share issuance costs    19,218 
Payments made for financing obligations and finance lease (316)  (941)
Net cash (used in) provided by financing activities- continuing operations (16,791)  9,955 
Net cash used in financing activities- discontinued operations    (5,539)
Net cash (used in) provided by financing activities (16,791)  4,416 
      
Net increase in cash and cash equivalents and restricted cash during the period 4,761   8,659 
Net effects of foreign exchange 383   (901)
Cash and cash equivalents and restricted cash, beginning of the period 25,347   26,763 
Cash and cash equivalents and restricted cash, end of the period$30,491  $34,521 
      
Supplemental disclosure with respect to cash flows     
Income taxes paid (refund received)$(8,116) $(4,582)
Interest paid$12,599  $9,259 
Lease termination fee paid$271  $ 
Non-cash transactions     
Equity and warrant liability issued for acquisitions and non-controlling interest$4,674  $10,267 
Shares issued for legal and liability settlement$  $794 
Distribution payable to non-controlling interests$719  $ 
Accrued capital purchases$811  $529 


TerrAscend Corp.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Amounts expressed in thousands of United States dollars, except for percentages)(unaudited)

The table below reconciles net loss from continuing operations to EBITDA from continuing operations and Adjusted EBITDA from continuing operations:

  For the Three Months Ended 
  June 30, 2024  June 30, 2023 
Revenue, net $77,523   72,124 
       
Net loss  (6,237) $(13,476)
Net loss margin %  -8.0%  -18.7%
       
Loss from discontinued operations     621 
Loss from continuing operations  (6,237)  (12,855)
       
Add (deduct) the impact of:      
Provision for income taxes  10,729   6,448 
Finance expenses  9,132   7,963 
Amortization and depreciation  4,993   4,991 
EBITDA from continuing operations  18,617   6,547 
Add (deduct) the impact of:      
Share-based compensation  1,960   1,981 
Loss from revaluation of contingent consideration  1,827    
Bad debt recovery  (4,169)   
Other one-time items  1,176   2,932 
Loss (gain) on lease termination and derecognition of ROU asset  (1,169)   
Gain on fair value of derivative liabilities and purchase option derivative assets  (2,922)  (215)
Impairment of property and equipment     10 
Gain on disposal of fixed assets  (17)   
Unrealized and realized loss on investments  227   1,661 
Unrealized and realized foreign exchange loss (gain)  104   (101)
Adjusted EBITDA from continuing operations $15,634  $12,815 
Adjusted EBITDA Margin from continuing operations  20.2%  17.8%


The table below reconciles Net cash provided by (used in) operating activities – continuing operations to Free Cash Flow:

  For the Three Months Ended 
  June 30, 2024  June 30, 2023 
Net cash provided by operating activities- continuing operations $13,129  $1,830 
Capital expenditures for property and equipment  (1,476)  (2,007)
Free Cash Flow $11,653  $(177)


The table below reconciles Revenue, net to General & Administrative expenses excluding stock-based compensation as a percentage of revenue, net:

  For the Three Months Ended 
  June 30, 2024  June 30,
2023
 
Revenue, net $77,523  $72,124 
       
General & Administrative expenses  24,060   30,476 
Less: stock-based compensation  1,960   1,981 
General & Administrative expenses excluding stock-based compensation $22,100  $28,495 
       
G&A excluding stock-based compensation as a % of revenue, net  28.5%  39.5%

FAQ

What was TerrAscend's (TSNDF) net revenue for Q2 2024?

TerrAscend's net revenue for Q2 2024 was $77.5 million, representing a 7.5% increase year-over-year.

How much free cash flow did TerrAscend (TSNDF) generate in Q2 2024?

TerrAscend generated $11.7 million in free cash flow during Q2 2024, compared to negative $0.2 million in Q2 2023.

What was TerrAscend's (TSNDF) market position in New Jersey during the first half of 2024?

TerrAscend maintained the #1 market share position in New Jersey throughout the first half of 2024, according to BDSA.

How much did TerrAscend's (TSNDF) wholesale revenue grow in Q2 2024?

TerrAscend's wholesale revenue increased by 75% year-over-year, led by growth in New Jersey, Pennsylvania, and Maryland.

What was the value of the senior secured term loan TerrAscend (TSNDF) closed in August 2024?

TerrAscend closed a senior secured term loan for gross proceeds of $140 million in August 2024.

TERRASCENT CORP

OTC:TSNDF

TSNDF Rankings

TSNDF Latest News

TSNDF Stock Data

271.44M
235.85M
7.06%
5.79%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Mississauga